アジア太平洋地域の乳がん診断市場、検査タイプ別（画像、生検、ゲノム検査、血液検査など）、タイプ別（乳管内癌、浸潤性乳管癌、炎症性乳癌、転移性乳癌）、エンドユーザー別（病院、診療所、研究・学術機関、診断センターなど）、流通チャネル別（直接入札、小売販売など）、2030年までの業界動向および予測。
アジア太平洋地域の乳がん診断市場分析と洞察
乳がんは人口の中で最も一般的な疾患であり、主に増殖性疾患を持つ女性に発症します。乳がんは主に乳房組織で発生します。乳がんの症状には、乳房のしこり、乳房の大きさや形の差、乳首からの分泌物、皮膚の炎症を起こした鱗状の赤い斑点などがあります。女性の乳がん発症率は、薬剤の進歩に伴い乳がん市場の成長とともに毎年増加しています。先進技術を用いた乳がん診断法の進歩。乳がん分野で開発された技術は、有効性、精度、効率性、信頼性、結果の迅速性を高め、疾患の検出精度を向上させることで向上しています。より短時間でがんを検出するための高度な機能。がんを早期に発見することで、患者の回復を早め、がん細胞の他の部位への転移を防ぎ、市場に出ている新薬で治療することができます。腫瘍スクリーニングと画像診断の増加は、乳がん市場を牽引するでしょう。これにより、乳がん患者数が毎年増加し、乳がんからの回復率も向上しているため、乳がん市場は拡大しています。新薬開発プロジェクトの可用性を高め、治療の有効性と効率性を高め、新薬を医療分野に統合することによる政府の支援。
しかし、がん診断治療のコストの高さと熟練した専門家の不足が、市場の成長を抑制している要因となっています。
データブリッジ・マーケット・リサーチは、アジア太平洋地域の乳がん診断市場は2030年までに17億5,750万米ドルに達し、予測期間中に年平均成長率（CAGR）10.3%で成長すると分析しています。アジア太平洋地域における乳がん患者の増加と乳がん治療における技術進歩により、検査タイプが診断タイプセグメントの中で最大のシェアを占めています。本市場レポートでは、価格分析、特許分析、技術進歩についても詳細に解説しています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2023年から2030年 |
|
基準年 |
2022 |
|
歴史的な年 |
2021年（2020～2016年にカスタマイズ可能） |
|
定量単位 |
売上高（百万米ドル）、販売数量（個数）、価格（米ドル） |
|
対象セグメント |
検査タイプ（画像、生検、ゲノム検査、血液検査など）、タイプ（乳管内癌、浸潤性乳管癌、炎症性乳癌、転移性乳癌）、エンドユーザー（病院、診療所、研究・学術機関、診断センターなど）、流通チャネル（直接入札、小売販売など）別。 |
|
対象国 |
中国、日本、インド、オーストラリア、韓国、シンガポール、マレーシア、タイ、インドネシア、フィリピン、その他のアジア太平洋地域。 |
|
対象となる市場プレーヤー |
この市場で取引を行っている主な企業としては、F-Hoffmann La Roche Ltd.、Siemens Healthcare GmbH、General Electric、Koninklijke Philips NV、FUJIFILM Corporation、Abbott、Hologic, Inc.、OncoStem、Provista Diagnostics、Thermo Fisher Scientific Inc.、Myriad Genetics, Inc.、Illumina, Inc.、Bio-Rad Laboratories, Inc.、BD、NanoString.、Cepheid、BIOMÉRIEUX、Exact Sciences Corporation、Biocept, Inc.、Abacus ALS などがあります。 |
アジア太平洋地域の乳がん診断市場の定義
乳がんは、乳房組織における悪性細胞の制御不能な増殖により生じる疾患で、男性よりも女性に多く見られます。乳がんは、乳腺や乳管で最も多くみられる乳腺細胞の制御不能な細胞分裂によって引き起こされます。乳がんの症状には、乳房のしこり、乳頭からの血性分泌物、乳頭または乳房の形状の変化などがあります。乳がんの治療は、がんの進行度によって異なります。化学療法、放射線療法、ホルモン療法、手術療法などが行われます。
乳がんは、男性よりも女性に多く見られるがんの一種です。この病気の症状には、生殖器からの出血、乳房内のしこりや塊、乳房や乳首の質感や形状の変化などがあります。乳がんの治療は、がんの進行度によって異なります。さらに、放射線療法、薬物療法、ホルモン療法、手術療法などが行われます。効果的な治療には、がんの早期発見が不可欠です。早期発見は、治療の選択肢の拡大、生存率の向上、生活の質の向上など、より良い結果につながります。急速に蔓延する病気のために、新しい治療法や治療法への圧力と需要が高まっています。
アジア太平洋地域の乳がん診断市場の動向
このセクションでは、市場の推進要因、利点、機会、制約、課題について理解を深めます。これらはすべて、以下で詳細に説明されています。
ドライバー
- 成長を支援するために技術的に高度な診断と治療を開始
乳がんは人口の中で最も多い疾患であり、主に増殖性疾患を持つ女性に発症します。乳がんは乳房組織で発生します。乳がんの症状には、乳房のしこり、乳房の大きさや形の異常、乳首からの分泌物、皮膚のかゆみを伴う鱗状の赤い斑点などがあります。この病気は全身に広がり、骨の痛み、リンパ節の腫れ、呼吸困難など、様々な症状が現れます。乳がん向けの新技術や治療法の研究開発が進むことで、市場の成長に大きく貢献するでしょう。
さらに、画像診断技術の進歩は、スクリーニングと早期発見の両方において新たな可能性を生み出しています。その一つが3Dマンモグラフィー（乳房トモシンセシスとも呼ばれます）です。この検査では、乳房の周囲の様々な角度から画像を撮影し、それらを3Dのような画像に合成します。
近年、いくつかの技術進歩ががん診断の運命を変えつつあります。前述のように、近年の進歩に加え、乳がん診断のプロセスを大きく変革しうるいくつかの技術が現在試験段階にあります。この分野におけるこれらの技術進歩は、アジア太平洋地域の乳がん診断市場を大きく牽引する要因となっています。
- 乳がんの罹患率の増加
アジア太平洋市場の成長を牽引する主要な要因の一つは、世界的な乳がん罹患率の増加です。これにより、正確かつ効果的な治療法を必要とする患者が増加すると予想されています。乳がんは世界で最も一般的ながんの一つであり、診断技術の向上により、今後診断される患者数は増加すると予想されています。
さらに、予防医療と早期治療の需要の高まりにより、がん検診が数多く行われるようになり、予測期間中に治療を強く必要とする患者の数も増加すると予想されます。
したがって、乳がんの罹患率が増加すると、症例の診断が増えるため、予測期間中に市場の成長を促進すると予想されます。
拘束
- 乳がん治療薬の副作用
スクリーニングとは、症状が現れる前の段階でがんを探すことです。これは、がんの早期発見に役立ちます。異常な組織やがんが早期に発見されれば、治療が容易になる可能性があります。症状が現れる頃には、がんがすでに転移し始めている場合もあります。乳がんの検出には、乳房磁気共鳴画像法、診断用マンモグラフィー、生検など、いくつかのスクリーニング検査が用いられます。これらの検査は乳がん診断の標準的な方法と考えられていますが、偽陰性、偽陽性、過度の精神的ストレス、過剰な放射線被曝、腫瘍破裂やがん細胞の転移といった副作用など、関連するリスクを伴います。
機会
- 政府の取り組み
政府は、患者の健康状態の改善を目指し、先進技術を用いた乳がん治療への取り組みを強化することに注力しています。一般の人々が治療を選択し、利用可能な医薬品や治療法を活用して生活の質を向上できるよう、給付金などの保険適用範囲が拡大されています。中国やインドなどの発展途上国では、政府が乳がんへの意識を高めるための様々なプログラムや取り組みを開始しています。これにより、乳がんの診断と治療管理に対する需要が大幅に増加しています。アジア太平洋地域の乳がん市場における主要なトレンドの一つとして、製薬会社と政府機関の合併・買収の増加が挙げられます。
乳がんの新規発症率は2010年から2019年にかけて年間0.6%増加し、死亡率は同期間に年間平均1.7%増加しました。乳がん患者数が増加するにつれて、がん診断における治療法や先進技術の利用が増加し、市場成長の機会となります。
チャレンジ
- 診断インフラの不足
乳がんをはじめとする非感染性疾患は、現在、国連とWHOによって重大な公衆衛生危機として認識されています。がんはこの問題の最大の部分を占めており、保健医療システムはがん治療の改善、費用抑制、そしてシステム効率の向上という大きな課題に直面しています。高所得国と低中所得国における治療アプローチと治療成績の差は顕著です。この格差の原因としては、費用、医療へのアクセス、人材と研修の不足、そして一般市民と医療関係者の認識不足などが挙げられます。
Moreover, compared to early diagnosis, cancer screening is a separate and more complex public health strategy that requires additional resources, infrastructure and coordination. Rural, developing and low income countries in the different regions does not have enough infrastructure to maintain with the new kits and fro the sample storage as well. These countries need diagnostic infrastructure to ensure the early detection and rapid, accurate diagnosis of the disease.
Post-COVID-19 Impact on Asia-Pacific Breast Cancer Diagnostics Market
The COVID-19 pandemic has caused disruptions in elective health services related to breast screening, pre-cancer care and management of abnormal screening results. This could lead to an increase in the incidence of breast cancer, exacerbating existing health inequalities.
Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities and product launch and strategic partnerships to improve the technology and test results involved in the market.
Recent Developments
- In November 2022, Koninklijke Philips N.V., announced the Asia-Pacific launch of a next-generation compact portable ultrasound solution at the Radiological Society of North America (RSNA) annual meeting to bring the diagnostic quality associated with premium cart-based ultrasound systems to more patients. It is portable and versatile with good image quality or performance. It is Compatible with Philips ultrasound systems Affiniti and EPIQ transducer. This has helped company to expand its product portfolio.
- In November 2022, Siemens Healthineers and Atrium Health, a leading not-for-profit healthcare provider known for leading pediatric, cancer and cardiac care programs, have announced a multi-year value partnership1. This strategic agreement focuses on improving access to care in Atrium Health's service area in the southeastern United States, improving health equity and increasing economic mobility. Atrium Health is acquiring more than $140 million in equipment and devices from Siemens Healthineers, including advanced imaging technology, radiation oncology and precision endovascular robotics. This has helped the company to expand their business.
Asia-Pacific Breast Cancer Diagnostics Market Scope
Asia-Pacific breast cancer diagnostics market is segmented into test type, type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE
- IMAGING
- BIOPSY
- GENOMIC TEST
- BLOOD TEST
- OTHERS
On the basis of test type, the Asia-Pacific breast cancer diagnostic market is segmented into imaging, biopsy, genomic test, blood tests and others.
ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TYPE
- DUCTAL CARCINOMA IN SITU
- INVASIVE DUCTAL CARCINOMA
- INFLAMMATORY BREAST CANCER
- 転移性乳がん
タイプに基づいて、アジア太平洋地域の乳がん診断市場は、乳管内癌、浸潤性乳管癌、炎症性乳がん、転移性乳がんに分類されます。
アジア太平洋地域の乳がん診断市場（エンドユーザー別）
- 病院
- クリニック
- 研究・学術機関
- 診断センター
- その他
エンドユーザーに基づいて、アジア太平洋地域の乳がん診断市場は、病院、診療所、研究・学術機関、診断センターなどに分類されます。
アジア太平洋地域の乳がん診断市場（流通チャネル別）
- 直接入札
- 小売売上高
- その他
流通チャネルに基づいて、アジア太平洋地域の乳がん診断市場は、直接入札、小売販売、その他に分類されます。
アジア太平洋地域の乳がん診断市場：地域分析/洞察
アジア太平洋地域の乳がん診断市場が分析され、検査タイプ、種類、エンドユーザー、流通チャネル別に市場規模の情報が提供されます。
この市場レポートで取り上げられている国は、中国、日本、インド、オーストラリア、韓国、シンガポール、マレーシア、タイ、インドネシア、フィリピン、およびその他のアジア太平洋諸国です。
2023年には、男性だけでなく主に女性人口の間で乳がんの増加により、中国がアジア太平洋地域を支配するでしょう。
本レポートの国別セクションでは、市場の現在および将来の動向に影響を与える、各国の市場影響要因と国内市場における規制変更についても解説しています。新規販売台数、交換販売台数、国の人口動態、規制法、輸出入関税といったデータは、各国の市場シナリオを予測する上で主要な指標として活用されています。また、アジア太平洋地域のブランドの存在と入手可能性、現地ブランドおよび国内ブランドとの競争の激しさまたは少なさによって直面する課題、そして販売チャネルの影響についても、国別データの予測分析において考慮されています。
競争環境とアジア太平洋地域の乳がん診断市場シェア分析
アジア太平洋地域の乳がん診断市場の競争環境は、競合他社ごとに詳細な情報を提供しています。企業概要、財務状況、収益、市場ポテンシャル、研究開発投資、新規市場への取り組み、生産拠点・設備、強みと弱み、製品発売、製品試験パイプライン、製品承認、特許、製品幅、アプリケーションの優位性、技術ライフラインカーブなどの詳細が含まれています。上記のデータは、アジア太平洋地域の乳がん診断市場における当社の注力分野にのみ関連しています。
アジア太平洋地域の乳がん診断市場で活動している主要企業としては、F-Hoffmann La Roche Ltd.、Siemens Healthcare GmbH、General Electric、Koninklijke Philips NV、FUJIFILM Corporation、Abbott、Hologic, Inc.、OncoStem、Provista Diagnostics、Thermo Fisher Scientific Inc.、Myriad Genetics, Inc.、Illumina, Inc.、Bio-Rad Laboratories, Inc.、BD、NanoString.、Cepheid、BIOMÉRIEUX、Exact Sciences Corporation、Biocept, Inc.、Abacus ALS などが挙げられます。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 TEST TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S 5 FORCES
5 EPIDEMIOLOGY
6 INDUSTRIAL INSIGHTS
7 REGULATORY FRAMEWORK
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 LAUNCH OF TECHNOLOGICALLY ADVANCED DIAGNOSIS & THERAPEUTICS TO AID GROWTH
8.1.2 INCREASING PREVALENCE OF BREAST CANCER
8.1.3 GROWING IMPORTANCE OF WOMEN'S HEALTH
8.1.4 RISING AWARENESS TOWARDS THE BREAST CANCER
8.2 RESTRAINTS
8.2.1 ADVERSE EFFECTS OF BREAST CANCER THERAPEUTICS
8.2.2 HIGH COST OF THE IMAGING SYSTEMS
8.3 OPPORTUNITIES
8.3.1 INITIATIVES TAKEN BY THE GOVERNMENT
8.3.2 STRATEGIC INITIATIVES TAKEN BY THE KEY MARKET PLAYERS
8.3.3 GROWTH IN RESEARCH AND DEVELOPMENT OF BREAST CANCER
8.4 CHALLENGES
8.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE
8.4.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF BREAST CANCER
9 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE
9.1 OVERVIEW
9.2 IMAGING
9.2.1 IONIZING BREAST IMAGING TECHNOLOGIES
9.2.1.1 FULL-FIELD DIGITAL MAMMOGRAPHY (FFDM)
9.2.1.2 ANALOG MAMMOGRAPHY
9.2.1.3 3D BREAST TOMOSYNTHESIS
9.2.1.4 POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY (PET/CT)
9.2.1.5 MOLECULAR BREAST IMAGING/ BREAST SPECIFIC GAMMA IMAGING (MBI/BSMI)
9.2.1.6 POSITRON EMISSION MAMMOGRAPHY
9.2.1.7 OTHERS
9.2.2 NON-IONIZING IMAGING TECHNOLOGIES
9.2.2.1 OPTICAL IMAGING
9.2.2.2 BREAST ULTRASOUND
9.2.2.3 BREAST MRI (MAGNETIC RESONANCE IMAGING)
9.2.2.4 AUTOMATED WHOLE BREAST ULTRASOUND (AWBU)
9.2.2.5 BREAST THERMOGRAPHY
9.2.3 BIOPSY
9.2.3.1 SURGICAL BIOPSY
9.2.3.2 FINE NEEDLE ASPIRATION BIOPSY
9.2.3.3 CORE NEEDLE BIOPSY
9.2.3.4 IMAGE-GUIDED BIOPSY
9.2.3.5 SENTINEL LYMPH NODE BIOPSY
9.2.4 GENOMIC TEST
9.2.4.1 MOLECULAR TESTING
9.2.4.1.1 PD-L1
9.2.4.1.2 MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR DNA MISMATCH REPAIR DEFICIENCY (DMMR)
9.2.4.1.3 NTRK GENE FUSIONS
9.2.4.1.4 PI3KCA GENE MUTATION
9.2.4.2 MAMMAPRINT
9.2.4.3 ONCOTYPE DX
9.2.4.4 OTHERS
9.3 BLOOD TEST
9.4 OTHERS
10 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TYPE
10.1 OVERVIEW
10.2 INVASIVE DUCTAL CARCINOMA
10.3 DUCTAL CARCINOMA IN SITU
10.4 INFLAMMATORY BREAST CANCER
10.5 METASTATIC BREAST CANCER
11 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 DIAGNOSTICS CENTERS
11.4 CLINICS
11.5 RESEARCH & ACADEMIC INSTITUTES
11.6 OTHERS
12 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
12.4 OTHERS
13 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY REGION
13.1 ASIA-PACIFIC
13.1.1 CHINA
13.1.2 INDIA
13.1.3 JAPAN
13.1.4 INDONESIA
13.1.5 PHILIPPINES
13.1.6 THAILAND
13.1.7 AUSTRALIA
13.1.8 MALAYSIA
13.1.9 SOUTH KOREA
13.1.10 SINGAPORE
13.1.11 REST OF ASIA-PACIFIC
14 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 HOLOGIC, INC.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 SIEMENS HEALTHCARE GMBH
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 F. HOFFMANN- LA ROCHE LTD
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 KONINKLIJKE PHILIPS N.V.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.5 ABBOTT
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENTS
16.6 ABACUS ALS
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENTS
16.7 BD
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 COMPANY SHARE ANALYSIS
16.7.4 PRODUCT PORTFOLIO
16.7.5 RECENT DEVELOPMENTS
16.8 BIOCEPT, INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENTS
16.9 BIOMÉRIEUX
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENTS
16.1 BIO-RAD LABORATORIES, INC.
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
16.11 CEPHEID
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENT
16.12 EXACT SCIENCES CORPORATION
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 COMPANY SHARE ANALYSIS
16.12.4 PRODUCT PORTFOLIO
16.12.5 RECENT DEVELOPMENTS
16.13 FUJIFILM CORPORATION
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENT
16.14 GENERAL ELECTRIC
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENTS
16.15 ILLUMINA, INC.
16.15.1 COMPANY SNAPSHOT
16.15.2 REVENUE ANALYSIS
16.15.3 PRODUCT PORTFOLIO
16.15.4 RECENT DEVELOPMENTS
16.16 MYRIAD GENETICS, INC.
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENT
16.17 NANOSTRING.
16.17.1 COMPANY SNAPSHOT
16.17.2 REVENUE ANALYSIS
16.17.3 PRODUCT PORTFOLIO
16.17.4 RECENT DEVELOPMENT
16.17.5 RECENT DEVELOPMENT
16.18 ONCOSTEM.
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENT
16.19 PROVISTA DIAGNOSTICS.
16.19.1 COMPANY SNAPSHOT
16.19.2 PRODUCT PORTFOLIO
16.19.3 RECENT DEVELOPMENT
16.2 THERMO FISHER SCIENTIFIC INC.
16.20.1 COMPANY SNAPSHOT
16.20.2 REVENUE ANALYSIS
16.20.3 PRODUCT PORTFOLIO
16.20.4 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
表のリスト
TABLE 1 INCIDENCE RATE OF BREAST CANCER (2020)
TABLE 2 MORTALITY RATE OF BREAST CANCER (2020)
TABLE 3 INCIDENCE OF DUCTAL CARCINOMA IN SITU (DCIS) BREAST CANCER
TABLE 4 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 5 ASIA PACIFIC IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 6 ASIA PACIFIC IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 7 ASIA PACIFIC IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 8 ASIA PACIFIC IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 9 ASIA PACIFIC NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 10 ASIA PACIFIC NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 11 ASIA PACIFIC BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 ASIA PACIFIC BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 13 ASIA PACIFIC BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 14 ASIA PACIFIC GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 ASIA PACIFIC GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 16 ASIA PACIFIC GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 17 ASIA PACIFIC MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 18 ASIA PACIFIC MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 19 ASIA PACIFIC BLOOD TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 ASIA PACIFIC OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 22 ASIA PACIFIC INVASIVE DUCTAL CARCINOMA IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 ASIA PACIFIC DUCTAL CARCINOMA IN SITU IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 ASIA PACIFIC INFLAMMATORY BREAST CANCER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 ASIA PACIFIC METASTATIC BREAST CANCER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 27 ASIA PACIFIC HOSPITALS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 ASIA PACIFIC DIAGNOSTIC CENTERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 ASIA PACIFIC CLINICS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 ASIA PACIFIC RESEARCH AND ACADEMIC INSTITUTES IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 ASIA PACIFIC OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 33 ASIA PACIFIC DIRECT TENDER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 ASIA PACIFIC RETAIL SALES IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 ASIA PACIFIC OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 37 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 38 ASIA-PACIFIC IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 39 ASIA-PACIFIC IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 40 ASIA-PACIFIC IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 41 ASIA-PACIFIC NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 42 ASIA-PACIFIC NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 43 ASIA-PACIFIC BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 44 ASIA-PACIFIC BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 45 ASIA-PACIFIC GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 46 ASIA-PACIFIC GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 47 ASIA-PACIFIC MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 48 ASIA-PACIFIC MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 49 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 50 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 51 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 52 CHINA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 53 CHINA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 54 CHINA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 55 CHINA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 56 CHINA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 57 CHINA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 58 CHINA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 59 CHINA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 60 CHINA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 61 CHINA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 62 CHINA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 63 CHINA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 64 CHINA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 65 CHINA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 66 CHINA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 67 CHINA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 68 CHINA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 69 CHINA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 70 CHINA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 71 CHINA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 72 INDIA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 73 INDIA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 74 INDIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 75 INDIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 76 INDIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 77 INDIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 78 INDIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 79 INDIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 80 INDIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 81 INDIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 82 INDIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 83 INDIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 84 INDIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 85 INDIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 86 INDIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 87 INDIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 88 INDIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 89 INDIA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 90 INDIA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 91 INDIA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 92 JAPAN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 93 JAPAN IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 94 JAPAN IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 95 JAPAN IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 96 JAPAN IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 97 JAPAN NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 98 JAPAN NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 99 JAPAN NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 100 JAPAN BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 101 JAPAN BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 102 JAPAN BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 103 JAPAN GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 104 JAPAN GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 105 JAPAN GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 106 JAPAN MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 107 JAPAN MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 108 JAPAN MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 109 JAPAN BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 110 JAPAN BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 111 JAPAN BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 112 INDONESIA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 113 INDONESIA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 114 INDONESIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 115 INDONESIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 116 INDONESIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 117 INDONESIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 118 INDONESIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 119 INDONESIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 120 INDONESIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 121 INDONESIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 122 INDONESIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 123 INDONESIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 124 INDONESIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 125 INDONESIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 126 INDONESIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 127 INDONESIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 128 INDONESIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 129 INDONESIA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 130 INDONESIA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 131 INDONESIA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 132 PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 133 PHILIPPINES IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 134 PHILIPPINES IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 135 PHILIPPINES IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 136 PHILIPPINES IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 137 PHILIPPINES NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 138 PHILIPPINES NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 139 PHILIPPINES NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 140 PHILIPPINES BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 141 PHILIPPINES BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 142 PHILIPPINES BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 143 PHILIPPINES GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 144 PHILIPPINES GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 145 PHILIPPINES GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 146 PHILIPPINES MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 147 PHILIPPINES MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 148 PHILIPPINES MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 149 PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 150 PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 151 PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 152 THAILAND BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 153 THAILAND IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 154 THAILAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 155 THAILAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 156 THAILAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 157 THAILAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 158 THAILAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 159 THAILAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 160 THAILAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 161 THAILAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 162 THAILAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 163 THAILAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 164 THAILAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 165 THAILAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 166 THAILAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 167 THAILAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 168 THAILAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 169 THAILAND BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 170 THAILAND BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 171 THAILAND BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 172 AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 173 AUSTRALIA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 174 AUSTRALIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 175 AUSTRALIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 176 AUSTRALIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 177 AUSTRALIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 178 AUSTRALIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 179 AUSTRALIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 180 AUSTRALIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 181 AUSTRALIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 182 AUSTRALIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 183 AUSTRALIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 184 AUSTRALIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 185 AUSTRALIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 186 AUSTRALIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 187 AUSTRALIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 188 AUSTRALIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 189 AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 190 AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 191 AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 192 MALAYSIA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 193 MALAYSIA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 194 MALAYSIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 195 MALAYSIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 196 MALAYSIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 197 MALAYSIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 198 MALAYSIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 199 MALAYSIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 200 MALAYSIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 201 MALAYSIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 202 MALAYSIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 203 MALAYSIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 204 MALAYSIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 205 MALAYSIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 206 MALAYSIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 207 MALAYSIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 208 MALAYSIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 209 MALAYSIA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 210 MALAYSIA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 211 MALAYSIA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 212 SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 213 SOUTH KOREA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 214 SOUTH KOREA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 215 SOUTH KOREA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 216 SOUTH KOREA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 217 SOUTH KOREA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 218 SOUTH KOREA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 219 SOUTH KOREA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 220 SOUTH KOREA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 221 SOUTH KOREA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 222 SOUTH KOREA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 223 SOUTH KOREA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 224 SOUTH KOREA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 225 SOUTH KOREA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 226 SOUTH KOREA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 227 SOUTH KOREA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 228 SOUTH KOREA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 229 SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 230 SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 231 SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 232 SINGAPORE BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 233 SINGAPORE IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 234 SINGAPORE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 235 SINGAPORE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 236 SINGAPORE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 237 SINGAPORE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 238 SINGAPORE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 239 SINGAPORE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 240 SINGAPORE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 241 SINGAPORE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 242 SINGAPORE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 243 SINGAPORE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 244 SINGAPORE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 245 SINGAPORE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 246 SINGAPORE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 247 SINGAPORE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 248 SINGAPORE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 249 SINGAPORE BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 250 SINGAPORE BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 251 SINGAPORE BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 252 REST OF ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
図表一覧
FIGURE 1 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 11 GROWING AWARENESS OF BREAST CANCER AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030
FIGURE 12 THE IMAGING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET
FIGURE 14 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2022
FIGURE 15 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 16 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, CAGR (2023-2030)
FIGURE 17 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, LIFELINE CURVE
FIGURE 18 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, 2022
FIGURE 19 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, 2023-2030 (USD MILLION)
FIGURE 20 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, CAGR (2023-2030)
FIGURE 21 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, LIFELINE CURVE
FIGURE 22 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY END USER, 2022
FIGURE 23 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION)
FIGURE 24 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030)
FIGURE 25 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE
FIGURE 26 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022
FIGURE 27 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 28 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 29 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 30 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 31 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 32 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 33 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 34 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030)
FIGURE 35 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
